Trial Summary
What is the purpose of this trial?The purpose of this phase I clinical trial is to test the safety of these CAR T cells in patients with myeloma.
There are two parts of this study. Part 1 of the study consists of screening for BCMA, Lenalidomide assignment and cell collection. Part 2 of the study is treatment with modified CAR T cells.
Eligibility Criteria
This trial is for adults over 18 with Multiple Myeloma, who've had at least two prior treatments including specific therapies (IMiD and PI), and have persistent or worsening disease. They must have adequate organ function and not be pregnant, without certain severe health conditions like heart issues, active infections, or other cancers needing treatment.Inclusion Criteria
Your blood levels of hemoglobin, white blood cells, and platelets are within a certain range without needing extra blood or medication for at least 1 week.
I am 18 years old or older.
Your creatinine and bilirubin levels are not too high, and your liver enzymes (AST and ALT) are within a certain range.
+3 more
Exclusion Criteria
I do not have any active cancer needing treatment except for skin cancer.
My heart's pumping ability is below normal.
I do not have HIV or active hepatitis B or C.
+12 more
Participant Groups
The study tests the safety of BCMA-targeted CAR T cells in treating myeloma. It has two parts: screening/assignment/cell collection and then treatment with modified CAR T cells. Some patients will also receive Lenalidomide to see if it improves outcomes.
1Treatment groups
Experimental Treatment
Group I: BCMA Targeted CAR T Cells with or without LenalidomideExperimental Treatment3 Interventions
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Memorial Sloan Kettering Cancer CenterNew York, NY
Loading ...
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
Juno Therapeutics, Inc.Industry Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyIndustry Sponsor